Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study

<u><b><i></i></b></u> <u><b><i>Background:</i></b></u> An anti-interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD), but its effectiveness on different anatomical sites and clinical signs remains unclear.<u><b><i>Objective:</i></b></u> To assess the effectiveness of tralokinumab on different anatomical sites and clinical signs of AD.<u><b><i>Methods:</i></b></u> This study included 129 moderate-to-severe AD patients treated with tralokinumab for 36 weeks. Eczema Area and Severity Index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper, and lower limbs) and four clinical signs (erythema, edema/papulation, excoriation, and lichenification) at weeks 0, 4, 12, 24, and 36.<u><b><i>Results:</i></b></u> Tralokinumab consistently reduced EASI scores on 4 anatomical sites and 4 clinical signs. The magnitude of decreasing EASI appeared highest on lower limbs while the achievement rates of EASI 75 at week 36 on 4 anatomical sites were mostly similar (72.6-77.6%). The magnitude of decreasing EASI and achieving EASI 75 or 100 appeared highest for excoriation, and the rates of EASI 75 at week 36 for erythema, excoriation, lichenification and edema/papulation were 71.1%, 69.4%, 68.4%, and 60.5%, respectively.<u><b><i>Conclusions:</i></b></u> Tralokinumab reduced EASI scores across various anatomical sites and clinical signs in moderate-to-severe AD patients. These findings suggest that tralokinumab may be widely useful for diverse skin manifestations of AD.